Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients

•Low-contact HCV treatment can succeed in populations that are less easily reached.•In this group of PWID, 93.5% of our patients successfully achieved SVR.•83.3% achieved SVR among the subset who were homeless.•Reducing demands on patients treated with MOUD is feasible. Healthcare delivery was disru...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The International journal of drug policy 2022-03, Vol.101, p.103570-103570, Article 103570
Hauptverfasser:	Sivakumar, Anishaa, Madden, Lynn, DiDomizio, Elizabeth, Eller, Anthony, Villanueva, Merceditas, Altice, Frederick L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Access Antiviral Agents Antiviral drugs Buprenorphine Coronaviruses COVID-19 Differentiated care models Drug policy Drug use Drug Users Drugs Evidence-based medicine HCV treatment Health care delivery Health education Health information Hepacivirus Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C - epidemiology Hepatitis C, Chronic - drug therapy HIV Human immunodeficiency virus Humans Implementation science Induction Male Medical screening Medical treatment Medications for opioid use disorder (MOUD) Methadone Narcotics Opioid-Related Disorders - drug therapy Opioid-Related Disorders - therapy Opioids Pandemics Patient-centered care Patients People who inject drugs (PWID) Pharmaceutical Preparations Phlebotomy Prisoners Referrals Research Paper SARS-CoV-2 Substance abuse treatment Substance Abuse, Intravenous - epidemiology Substance use disorder Syringe services programs Syringes Telemedicine Visits Workers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!